Alejandro D. Ricart

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Robert Chen, Pier Luigi Zinzani, Michelle A. Fanale et al. · Journal of Clinical Oncology · 2017 · 985 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

Philippe Armand, Margaret A. Shipp, Vincent Ribrag et al. · Journal of Clinical Oncology · 2016 · 672 citations

Medicine, Hematology, Oncology +17

A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors

Luis E. Raez, Kyriakos P. Papadopoulos, Alejandro D. Ricart et al. · Cancer Chemotherapy and Pharmacology · 2012 · 529 citations

Medicine, Oncology, Pharmacology +12

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

Hedy L. Kindler, Tatsuya Ioka, D. J. Richel et al. · The Lancet Oncology · 2011 · 396 citations

Medicine, Oncology, Pharmacology +7

Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

Monica Mita, Alain C. Mita, Quincy S. Chu et al. · Journal of Clinical Oncology · 2008 · 272 citations · Full text

Medicine, Oncology, Pharmacology +10